The relative orientation of the Arg and Asp side chains defined by a pseudodihedral angle as a key criterion for evaluating the structure-activity relationship of RGD peptides

Journal of Peptide Science

Volumn 10, Issue 8, 2004, Pages 494-509

  Kostidis, Sarantos ^a   Stavrakoudis, Athanassios ^a   Biris, Nikolaos ^a   Tsoukatos, Demokritos ^a   Sakarellos, Constantinos ^a   Tsikaris, Vassilios ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Integrin inhibitors; RGD conformation; RGD inhibitors; RGD SAR; RGD specificity; RGD structure activity

Indexed keywords

ARGININE; ARGINYLGLYCYLASPARTIC ACID; ASPARTIC ACID; CYCLOPEPTIDE; INTEGRIN; SCLEROPROTEIN;

ARTICLE; CALCULATION; CONTROLLED STUDY; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION;

AMINO ACID SEQUENCE; ANIMALS; ARGININE; ASPARTIC ACID; HUMANS; INTEGRINS; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PLATELET AGGREGATION; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4444279818     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.559     Document Type: Article

References (72)

1. Hynes RO. Integrins: a family of cell surface receptors. Cell 1987; 48: 549-554.
2. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
3. Ruoslahti E. RGD and other recognition sequences for integrins. Annu. Rev. Cell. Dev. Biol. 1996; 12: 697-715.
4. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491-497.
5. Pierschbacher MD, Ruoslahti E. Influence of stereo-chemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J. Biol. Chem. 1987; 262: 17294-17 298.
6. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J. Biol. Chem. 2000; 275: 21785-21788.
7. Torshin IY. Structural criteria of biologically active RGD-sites for analysis of protein cellular function: a bioinformatics study. Med. Sci. Monit. 2002; 8: 301-312. 1
8. Gould RJ, Polokof MA, Friedman PA, Huang TF, Holt JC, Cook JJ, Niewiarowski S. Disintegrin: a family of integrin inhibitory proteins from viper venoms. Proc. Soc. Exp. Biol. Med. 1990; 195: 168-171.
9. Ginsberg M, Pierschbacher MD, Ruoslahti E, Marguerie G, Plow E. Inhibition of fibronectin binding to platelets by proteolytic fragments and synthetic peptides which support fibroblast adhesion. J Biol. Chem. 1985; 260: 3931-3936.
10. Nicosia RF, Bonanno E. Inhibition of angiogenesis in vitro by Arg-Gly-Asp containing synthetic peptide. Am. J. Pathol. 1991; 138: 829-833.
11. Bronson RA, Fusi F. Evidence that an Arg-Gly-Asp adhesion sequence plays a role in mammalian fertilization. Biol. Reprod. 1990; 43: 1019-1025.
12. Ruggeri ZM. Receptor-specific antiplatelet therapy. Circulation 1989; 8O: 1920-1922.
13. Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: the responsive integrin. Cell 1991: 65: 359-362.
14. Kloczewiak M, Timmons S, Bednarek MA, Sakon M, Hawiger J. Platelet receptor recognition domain on the γ-chain of human fibrinogen and its synthetic peptide analogues. Biochemistry 1989; 28: 2915-2919.
15. Haverstick DM, Cowan JF, Yamada KM, Santoro SA. Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin. Blood 1985; 66: 946-952.
16. Plow EF, McEver BS, Coller BS, Woods VL, Marguerie GA, Ginsberg MH. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 1985; 66: 724-727.
17. Pytela RP, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp specific adhesion receptors. Science 1986; 231: 1559-1562.
18. Ruggeri ZM, De Marco L, Gatti L, Bader R, Montgomery RR. Platelets have more than one binding site for von Willebrand factor. J. Clin. Invest. 1983; 72: 1-12.
19. Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J. Biol. Chem. 1979; 254: 5357-5363.
20. Sims PJ, Ginsberg MH, Plow EF, Shattil SJ. Effect of platelet activation on the conformation of the plasma membrane glycoprotein IIb-IIIa complex. J. Biol. Chem. 1991; 266: 7345-7352.
21. Mayo KH, Fan F, Beavers MP, Eckardt A, Keane P, Hockstra WJ, Andrade-Gordon P. RGD induces conformational transition in purified platelet integrin GPIIb/IIIa-SDS system yielding multiple binding states for fibrinogen γ-chain C-terminal peptide. FEBS Lett. 1996; 378: 79-82.
22. 3. J. Biol. Chem. 2000; 275: 7249-7260.
23. Ojima I, Chakravarty S, Dong Q. Antithrombotic agents: from RGD to peptide mimetics. Bioorg. Med. Chem. 1995; 3: 337-360.
24. Pfaff M, Tangemann K, Muller B, Gurrath M, Muller G, Kessler H, Timpl R, Engel J. Selective recognition of cyclic RGD peptides of NMR defined conformation by αIIbβ3, αVβ3 and α 5β1 integrins. J. Biol. Chem. 1994; 269: 20233-20238.
25. Saudek V, Atkinson RA, Pelton JT. Three-dimensional structure of echistatin, the smallest active RGD protein. Biochemistry 1991; 30: 7369-7372.
26. Chen Y, Pitzenberger SM, Garsky VM, Lumma PK, Sanyal G, Baum J. Proton NMR assignments and secondary structure of the snake venom protein echistatin. Biochemistry 1991; 30: 11625-11636.
27. 1H NMR and restrained molecular dynamics. Int. J. Pept. Protein Res. 1994; 43: 563-572.
28. Adler M, Lazarus RA, Dennis MS, Wagner G. Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist. Science 1991; 253: 445-448.
29. 1H NMR assignments of kistrin, a potent platelet aggregation inhibitor and glycoprotein IIb-IIIa antagonist. Biochemistry 1992; 3: 1031-1039.
30. McDowell RS, Dennis MS, Louie A, Shuster M, Mulkerrin MG, Lazarus RA. Mambin, a potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor structurally related to the short neurotoxins. Biochemistry 1992; 31: 4766-4772.
31. Senn H, Maus W. The nuclear magnetic resonance solution structure of flavoridin, an antagonist of the platelet GP IIb-IIIa reccptor. J. Mol. Biol. 1993; 232: 907-925.
32. 1H NMR assignments and secondary structure of dendroaspin, an RGD-containing glycoprotein IIb-IIIa (αIIb-β3 antagonist with a neurotoxin fold. Eur. J. Biochem. 1994; 226: 861-868.
33. Krezel AM, Wagner G, Seymour-Ulmer J, Lazarus RA. Structure of the RGD protein decorsin: conserved motif and distinct function in leech proteins that affect blood clotting. Science 1994; 264: 1944-1947.
34. 1H NMR spectroscopy and simulated annealing calculations. Int. J. Pept. Protein Res. 1996; 48: 220-228.
35. Krezel AM, Ulmer JS, Wagner G, Lazarus RA. Recombinant decorsin: dynamics of the RGD recognition site. Protein Sci. 2000; 9: 1428-1438.
36. Samanen J, Ali F, Romoff T, Calvo R, Sorenson E, Vasko J, Storer B, Berry D, Bennett D, Strohsacker M, Powers D, Stadel J, Nichols A. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. J. Med. Chem. 1991; 34: 3114-3125.
37. Yamada KM. Adhesive recognition sequences. J. Biol. Chem. 1991; 266: 12809-12812.
38. Hynes RA, Lander AD. Contact and adhesive specificities in the associations, migrations, and targeting of cells and axons. Cell 1992; 68: 303-322.
39. D'Souza SE, Ginsberg M, Plow EF. Arginyl-glycylaspartic acid (RGD): a cell adhesion motif. Trends Biochem. Sci. 1991; 16: 246-250.
40. Lanza P, Felding-Habermann B, Ruggeri ZM, Zanetti M, Billetta R. Selective interaction of a conformationally-constrained Arg-Gly-Asp (RGD) motif with the integrin receptor αvβ3 expressed on human tumor cells. Blood Cells Mol. Dis. 1997; 23: 230-241.
41. Mayo KH, Fan F, Beavers MP, Eckardt A, Keane P, Hoekstra WJ, Andrade-Gordon P. NOE-derived conformation of GRGDSP cell adhesion recognition site in the presence of SDS micelles and integrin receptor GPIIB/IIIA. Biochim. Biophys. Acta 1996; 1296: 95-102.
42. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 1991; 291: 50-54.
43. Bach AC, Eyermann CJ, Gross JD, Bower MJ, Harlow RL, Weber PC, DeGrado WF. Structural studies of a family of high affinity ligands for GPIIb/IIIa. J. Am. Chem. Soc. 1994; 116: 3207-3219.
44. Mer G, Kellenberger E, Lefevre J-F. α-Helix mimicry of a β-turn. J. Mol. Biol. 1998; 281: 235-240.
45. McDowell RS, Blackburn BK, Gadek TR, McGee LR, Rawson T, Reynolds ME, Robarge KD, Somers TC, Thorsett ED, Tischler M, Webb RR, Venuti MC. From peptide to non-peptide 2. The de novo design of potent, non-peptidal inhibitors of platelet aggregation based on a benzodiazepinedione scaffold. J. Am. Chem. Soc. 1994; 116; 5077-5083.
46. Johnson WC, Pagano TG, Basson CT, Madri JA, Gooley P, Armitage IM. Biologically active Arg-Gly-Asp oligopeptides assume a type II β-turn in solution. Biochemistry 1993; 32: 268-273.
47. 3 antagonists. J. Am. Chem. Soc. 1996; 118: 7461-7472.
48. Bach AC, Espina JR, Jackson SA, Stouten PFW, Duke JL, Mousa SA, DeGrado WF. Type II' to type I β-turn swap changes specificity for integrins. J. Am. Chem. Soc. 1996; 118: 293-294.
49. Assa-Munt N, Jia X, Laakkonen P, Ruoslahti E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 2001; 40: 2373-2378.
50. 3 integrin antagonists. J. Med. Chem. 1999; 42: 3033-3040.
51. Miyashita M, Akamatsu M, Hayashi Y, Ueno T. Three-dimensional quantitative structure-activity relationship analyses of RGD mimetics as fibrinogen receptor antagonists. Bioorg. Med. Chem. Lett. 2000; 10: 859-863.
52. Craig WS, Cheng S, Mullen D, Blevitt J, Pierschbacher MD. Concept and progress in the development of RGD-containing peptide pharmaceuticals. Biopolymers 1995; 37: 157-175.
53. Lu X, Sun Y, Shang D, Wattam B, Egglezou S, Hughes T, Hyde E, Scully M, Kakkar V. Evaluation of the role of proline residues flanking the RGD motif of dendroaspin, an inhibitor of platelet aggregation and cell adhesion. Biochem.J. 2001; 355: 633-638.
54. Zachariah C, Cameron A, Lindberg I, Kao KJ, Beinfeld MC, Edison AS. Structural studies of a neuropeptide precursor protein with an RGD proteolytic site. Biochemistry 2001; 40: 8790-8799.
55. Stavrakoudis A, Bizos G, Eleftheriadis D, Kouki A, Panou-Pomonis E, Sakarellos-Daitsiotis M, Sakarellos C, Tsoukatos D, Tsikaris V. A three-residue cyclic scaffold of non-RGD containing peptide analogues as platelet aggregation inhibitors: design, synthesis, and structure-function relationships. Biopolymers 2001; 56:20-26.
56. Stavrakoudis A, Tsoukatos D, Sakarellos-Daitsiotis M, Sakarellos C, Tsikaris V. Studies on the structure-function relationships of cyclic non-RGD peptides. In Peptides 2000, Martinez J, Fehrentz JA. (eds). EDK: Paris, 2001; 439-440.
57. DRGDW peptides determined by molecular dynamics simulations. Theor. Chem. Ace. 2001; 106: 128-136.
58. Bartels C, Stote RH, Karplus M. Characterization of flexible molecules in solution: the RGDW peptide. J. Mol. Biol. 1998; 284: 1641-1660.
59. 2 peptide as a probe of slow conformational exchange of short linear peptides in DMSO. Biopolymers 2003; 69: 72-86.
60. n) for multiple anchoring of antigenic peptides: application to the acetylcholine receptor (AChR) main immunogenic region. Int. J. Biol. Macromol. 1996; 19: 195-205.
61. Tsikaris V, Sakarellos C, Cung MT, Marraud M, Sakarellos-Daitsiotis M. Concept and design of a new class of sequential oligopeptide carriers (SOC) for covalent attachment of multiple antigenic peptides. Biopolymers 1996; 38: 291-293.
62. Stewart JM, Young JD (eds). Solid Phase Peptide Synthesis. Pierce Chem. Co.: Rockford, IL, 1984; 71-95.
63. Güntert P, Mumenthaler C, Wüthrich K. Torsion angle dynamics for NMR structure calculation with the new program DYANA. J. Mol. Biol. 1997; 273: 283-298.
64. Wüthrich K, Billeter M, Braun W. Pseudo-structures for the 20 common amino acids for use in studies of protein conformations by measurements of intramolecular proton-proton distance constraints with nuclear magnetic resonance. J. Mol. Biol. 1983; 169: 949-961.
65. Koradi R, Billeter M, Wüthrich K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph. 1996; 14: 51-55.
66. 1H NMR studies on the preferred interactions of guanidinium and C-terminal carboxylate groups in arginine containing peptides. J. Chem. Soc., Perkin Trans. 2 1993; 1345-1349.
67. Tsikaris V, Sakarellos-Daitsiotis M, Tzovaras D, Sakarellos C, Orlewski P, Cung MT, Marraud M. Isomerization of the Xaa-Pro peptide bond induced by ionic interactions of arginine. Biopolymers 1996; 38: 672-673.
68. Benedetti E, Morelli G, Némethy G, Scheraga HA. Statistical and energetic analysis of side-chain conformations in oligopeptides. Int. J. Pept. Protein Res. 1983; 22: 1-15.
69. McGregor MJ, Islam SA, Sternberg MJ. Analysis of the relationship between side-chain confon-nation and secondary structure in globular proteins. J. Mol. Biol. 1987; 198: 295-310.
70. Jackson S, DeGrado W, Dwivedi A, Parthasarathy A, Higley A, Krywko J, Rockwell A, Markwalder J, Wells G, Wexler R, Mousa S, Harlow R. Template-constrained cyclic peptides: design of high-affinity ligands for GPIIb/IIIa. J. Am. Chem. Soc. 1994; 116: 3220-3230.
71. Markley JL, Bax A, Arata Y, Hilbers W, Kaptein R, Sykes BD, Wright PE, Wüthrich K. Recommendations for the presentation of NMR structures of proteins and nucleic acids. Pure Appl. Chem. 1998; 70: 117-142.
72. α-tetrasubstitution). Biopolymers (Pept. Sci.) 2001; 60: 396-419.